Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Base-case results

From: Impact of drug substitution on cost of care: an example of economic analysis of cetuximab versus panitumumab

  Panitumumab Cetuximab Difference
Life-month gained 7.84 7.92  
Total QALM 5.36 5.42  
Total QALY 0.45 0.45  
Total costs $66,006 $71,956  
Net monetary benefit $1044 $ (4193)  
Cost-effectiveness ratio $147,663 $159,281  
INMB $5237
ICER $1,251,775
  1. QALM quality-adjusted life month, QALY quality-adjusted life year, INMB incremental net monetary benefit, ICER incremental cost-effectiveness ratio